In order to enable the most accurate early detection of cancer, GRAIL is conducting what we believe to be one of the largest clinical study programs ever pursued in genomic medicine. We are collaborating with leading community and academic medical centers to conduct studies enrolling tens of thousands of people to identify the patterns required to detect many types of cancer, and to validate GRAIL’s products.
Interested in participating in one of our groundbreaking studies? See if you are eligible below and sign up here to receive updates.
Are you a clinical research center interested in collaborating with GRAIL on a study? Please contact email@example.com.
Circulating Cell-Free Genome Atlas Study (CCGA)
The purpose of the CCGA Study is to characterize the landscape of cell-free nucleic acid (cfNA) profiles in individuals with and without cancer. The observational CCGA Study is enrolling at least 15,000 individuals with and without cancer (70% with cancer and 30% without cancer), interrogating the biology of both tumor biopsy tissue samples and the circulating, cancer-defining nucleic acids in blood. cfNAs in the blood are an emerging biomarker for earlier cancer detection. GRAIL and its collaborators will collect clinical outcomes on the enrolled participants for a minimum of five years. The result is intended to be a detailed atlas of cancer genomics that will be used to support development of GRAIL products for early cancer detection.
Avera Research Institute, Benaroya Research Institute at Virginia Mason, Christ Hospital Health Network - The Lindner Cancer Center Research Division, Cleveland Clinic, Guardian Research Network, Hartford HealthCare Cancer Institute, Icahn School of Medicine at Mount Sinai, Lahey Hospital & Medical Center, Mayo Clinic (Arizona, Florida, and Minnesota), Memorial Sloan Kettering, Oregon Health & Science University Knight Cancer Institute, Tennessee Oncology, UHN Princess Margaret Cancer Centre (Canada), University of Miami Sylvester, and US Oncology Network
The study is designed to enroll approximately 10,500 participants with multiple types of malignancy and 4,500 participants without a clinical diagnosis of cancer. Individuals with a new diagnosis of cancer who have not yet received treatment are eligible to enroll. Individuals without a current or prior diagnosis of cancer are also eligible to enroll. All participants must be 20 years of age or older and be able to provide written consent.
The purpose of the STRIVE Study is to develop and validate blood tests for detection of multiple cancers at early stages. STRIVE is a multi-center, longitudinal, prospective, observational study that is designed to enroll up to 120,000 women at the time of their screening mammogram. Participants will complete a health questionnaire and provide a blood sample around the time of their screening mammogram and will be followed for five years to capture clinical outcomes, including cancer diagnoses.
Cleveland Clinic, Henry Ford Health System, Mayo Clinic, Sarah Cannon, Scottsdale Medical Imaging, and Sutter Health.
Women undergoing screening mammography at participating medical centers and who provide informed consent are eligible.